A Clinical Study to Evaluate Cyclopofol Injection for the Prevention of Postoperative Nausea and Vomiting

Sponsor
Mengchang Yang (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05837156
Collaborator
(none)
300
1
3
8
37.7

Study Details

Study Description

Brief Summary

This study uses cyclopropofol as a positive control and adopts a large sample, multi-center, random, double-blind and positive parallel control test design to explore the clinical application value of cyclopropofol in preventing postoperative nausea and vomiting.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

Before the end of the anesthesia maintenance period/operation, it was divided into groups A, B and C according to different drug regimens. The subjects were randomly assigned to one of them in a 1:1:1 ratio to receive cyclopophenol or sevoflurane anesthesia. Each group of subjects should be roughly consistent according to the proportion of each number of PO . After screening the object, the researchers of each testing center are confirmed by the researchers of the center, log in to the random system, fill in the screening information, obtain the random number information, and distribute the corresponding research drugs according to the random number. The number of random shelters is generated through SAS software, which is used as a centralized random grouping system to import the total number of drugs. This study sets up evaluation researchers and drug management researchers. The whole experimental process turned a blind eye to not only the subjects, but also the evaluators. This study has set up evaluation investigators and administrative investigators. Administrative researchers are only involved in the random grouping, dispensing and delivery process. Other processes, including the subject's informed consent, screening, efficacy indicators and safety evaluation, and planned visits, are completed by the evaluation investigators.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Clinical Study to Evaluate Cyclopofol Injection for the Prevention of Postoperative Nausea and Vomiting
Anticipated Study Start Date :
May 2, 2023
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: group cyclophenol

Calculated by body weight (kg), the initial dose of continuous infusion of cyclopophenol is 0.8 mg/kg/h. During the infusion, the researchers adjusted the rate according to the reaction of the subjects, and the adjustment range was 0.4 mg/kg/h-2.4 mg/kg/h.

Drug: Cyclophenol
Cyclophenol only

Active Comparator: group heptaflurane

The anesthetic sevoflurane is inhaled for anesthesia maintenance. The initial concentration of sevoflurane is 1.5-2.0%, which can be adjusted to the expected effect according to the subject's reaction.

Drug: Heptaflurane
Heptaflurane only

Experimental: group heptaflurane combined cyclophenol

Inhaled anesthetic sevoflurane combined with a small dose of cyclopophenol for anesthesia maintenance. The initial concentration of sevoflurane is 0.5%, and the initial dose of cyclopophenol is 0.4 mg/kg/h.After that, sevoflurane or cyclopophenol (with an adjustment range of 0.2 mg/kg/h-1.2 mg/kg/h) can be adjusted to the expected effect according to the subject's reaction.

Drug: Heptaflurane combined Cyclophenol
Heptaflurane combined Cyclophenol

Outcome Measures

Primary Outcome Measures

  1. The incidence of PONV within 24 hours after each group's operation. [Day 1]

    PONV incidence (%) = (number of patients with nausea and vomiting / number of PONV incidence (%) = (number of patients with nausea and vomiting / number of people in the group) × 100%

Secondary Outcome Measures

  1. The incidence of nausea and vomiting within 48 hours after surgery in each group [Day 2]

    PONV incidence (%) = (number of patients with nausea and vomiting / number of PONV incidence (%) = (number of patients with nausea and vomiting / number of people in the group) × 100%

  2. The average number of rescuers in each group within 24 hours after surgery [Day 1]

    Severe vomiting (level 3 or above) requires rescue treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. At least 2 of the 4 induced risk factors of PONV (risk factors are: history of PONV or motion sickness, habitual non-smoking, women, receiving opioid analgesia).

  2. Selective surgery that requires tracheal intubation (non-emergency, non- cardiothoracic surgery and non-intracranial surgery, laparoscopic surgery, gastrointestinal surgery, obstetrics and gynecology surgery, tympanoplasty, tonsillectomy, etc. The operation time is expected to last at least 1 hour) The subjects need to be hospitalized overnight after surgery. The operation time is defined as from the beginning of the study of the drug to the completion of the last stitch.

  3. Male or female, age ≥ 18 years old, ASA-PS score I to III.

Exclusion Criteria:
  1. There is a history of vestibular nerve disorder or dizziness or nausea and vomiting 24 hours before the operation; or receiving conventional antiemetic treatment.

  2. The subjects who need to maintain ventilation after surgery or need to place the nasogastric tube in place for a period of time.

  3. The subject who the researcher believes that there are any other factors that are not suitable to participate in the research.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sichuan Provincial People's Hospital Sichuan China

Sponsors and Collaborators

  • Mengchang Yang

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mengchang Yang, Deputy Chief Physician, Sichuan Provincial People's Hospital
ClinicalTrials.gov Identifier:
NCT05837156
Other Study ID Numbers:
  • 950429
First Posted:
May 1, 2023
Last Update Posted:
May 1, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mengchang Yang, Deputy Chief Physician, Sichuan Provincial People's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 1, 2023